Comments
The United States Food and Drug Administration (US FDA) has cleared Montelukast Sodium, a bulk drug/ API manufactured by Morepen Laboratories , for sale in the US market. This gives Morepen an entry into the ₹2,000-crore (approx. $300 million) US market for Montelukast. The first commercial orders for the bulk drug are expected in Q2 FY 2018-19. Shares of Morepen Labs jumped 20 per cent at ₹30.30 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.